2025

Paul McKeigue: University of Edinburgh, United Kingdom
Identifying drug targets for type 1 diabetes by genome-wide aggregated trans-effects analysis

Paolo Monti: San Raffaelle Vita-Salute University, Italy
Combination CAR-Tregs to promote immune tolerance in iPSC-derived ß-cell replacement therapy

Joachim Størling: Steno Diabetes Center Copenhagen, Denmark
Pyroptosis as a driver of islet inflammation and ß-cell destruction in type 1 diabetes

2024

Nordin Hanssen: Amsterdam UMC - Netherlands
Inulin supplementation in adults with type 1 diabetes: low risk, high return?

Arturo Roca Rivada: Free University of Brussels - Belgium
The type 1 diabetes candidate genes PTPN2 and BACH2 as checkpoints for beta cell immunomodulation: Exploring a novel crosstalk

Teresa Rodriguez-Calvo: Helmholtz Munich - Germany
Uncovering novel immune landscapes in type 1 diabetes with spatial proteomics

Sylvaine You: French National Institute of Health and Medical Research (INSERM) - Paris, France
Prevention of type 1 diabetes by human PD-1 agonists